VSTM, US92337C2035

Verastem reports 50 percent response rate. Verastem stock is valued at USD 890.7 million

Published on 10/29/2026 at 13:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Verastem stock costs EUR 8.89 on October 29, 2026. Third-quarter results are scheduled for November 5, 2026, with revenue guidance of USD 23.9-24.1 million.

Clinical data and capital position

Verastem reported a 41 percent confirmed response rate in second-line-or-later pancreatic cancer on October 14, 2026.
Cash, cash equivalents and investments were estimated at USD 172.8 million on September 30, 2026.
The company reported a 2 percent treatment discontinuation rate from adverse events at the 900 mg dose.

VSTM, US92337C2035, Illustration mit AI erstellt.

Verastem, Inc. (ISIN US92337C2035) reported a 50 percent confirmed response rate and a USD 890.7 million market value after its October 14, 2026 clinical update. The company said its VS-7375 program produced responses across pancreatic, colorectal and lung cancer cohorts, while its next results release is scheduled for November 5, 2026, according to Verastem and Verastem investor relations.

Response data set the tone

The October 14 release covered the TARGET-D 101 Phase 1/2 study of VS-7375, an investigational KRAS G12D inhibitor. In the broader second-line-or-later pancreatic cohort, the confirmed objective response rate was 41 percent among 22 patients as of the October 7, 2026 data cutoff, with a disease-control rate of 86 percent. The six-month progression-free survival rate was 67 percent.

The company also reported a 43 percent confirmed response rate in second-line-or-later non-small cell lung cancer at 600 mg once daily. In third-line-or-later colorectal cancer, the 900 mg combination with anti-EGFR therapy produced a 33 percent objective response rate. These figures remain early clinical results, and Verastem said follow-up and enrollment are continuing.

What does the financing picture show?

Preliminary third-quarter figures filed with the SEC put net product revenue at USD 23.9 million to USD 24.1 million for the three months ended September 30, 2026, versus USD 11.2 million a year earlier. Cash, cash equivalents and investments were estimated at USD 172.8 million, compared with USD 137.7 million on September 30, 2025. The filing also said CEO Daniel Paterson will retire effective January 1, 2027, with Michael Bailey appointed as successor. The figures and management transition came from the company's SEC filing.

Key dates for the program

Verastem initiated the TARGET-D 201 trial on June 16, 2026, reported the October 7 data cutoff, and published the multi-tumor update on October 14, 2026. The company plans to open the first-line pancreatic Phase 3 trial by year-end 2026. Its next scheduled reporting event is the third-quarter earnings call on November 5, 2026, at 4:30 p.m. ET, as stated by Verastem.

Stock indication in euros

Verastem stock was trading at EUR 8.89 at Lang & Schwarz on October 29, 2026 at 1:36 p.m. CEST. The primary listing is on the Nasdaq Capital Market in USD, and the 52-week range was USD 3.43 to USD 10.82.

The further course of trading is shown by the continuously updated real-time quote of Verastem stock.